Farmaci orfani e malattie rare: un confronto internazionale delle normative di riferimento

Farmaci orfani e malattie rare: un confronto internazionale delle normative di riferimento

Authors

  • S. Martina Laurea in Economia e Commercio. CESAV (Centro di Economia Sanitaria A. e A. Valenti) dell’Istituto per le Ricerche Farmacologiche M Negri

  • C. Denti Laurea in Economia e Commercio. CESAV (Centro di Economia Sanitaria A. e A. Valenti) dell’Istituto per le Ricerche Farmacologiche M Negri

  • L. Garattini Laurea in Economia e Commercio. CESAV (Centro di Economia Sanitaria A. e A. Valenti) dell’Istituto per le Ricerche Farmacologiche M Negri



DOI:

https://doi.org/10.7175/fe.v2i3.732

Abstract

Orphan drugs are defined as medicines with low economic returns, so that their production is not a profitable business far pharmaceutical companies. The present study analyses the main characteristics and the role of orphan drugs in four countries (United States of America, .Japan, Australia and European Union), by considering the regulation and the market situation of each State. All countries have introduced a specific legislation on orphan drugs to stimulate the research activity of pharmaceutical industry. The first law was the Orphan Drug Act of the United States of America in 1982. A common limit of all regulations is the strict correlation between “orphan drugs” and “rare diseases”. In fact, the term “orphan” does not refer only to rare disease, but also to other elements that can determine low economic returns for the industry (e.g. drugs with high cost of research and development, drugs that cannot be patented).

Downloads

Published

2001-09-15

How to Cite

Martina, S., Denti, C., & Garattini, L. (2001). Farmaci orfani e malattie rare: un confronto internazionale delle normative di riferimento. Farmeconomia. Health Economics and Therapeutic Pathways, 2(3), 185–193. https://doi.org/10.7175/fe.v2i3.732

Issue

Vol. 2 No. 3 (2001)

Section

Methods

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
  4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)